BioSpace News Archive

TrueBinding, Inc. announced today that the company has been granted a Type B End-of-Phase 2 (EOP2) meeting with the U.S. Food & Drug Administration (FDA).

AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare diagnostic solutions development company, announced today the filing of a provisional patent application with the U.S. Patent and Trademark Office (US PTO) for the innovative use of proprietary materials in its ocular diagnostic assays that significantly increases sample disbursement.

IR-MED will be presenting its proprietary technology that is being designed to detect early-stage Pressure Injuries at the Annual Conference of the National Pressure Injury Advisory Panel – NPIAP 2023.

Milestone Scientific Inc., a leading developer of computerized drug delivery instruments that provide painless and precise injections, announced that it has commenced sales of CompuFlo® Epidural disposables into the University Pain and Spine Center, which operates 7 offices across New Jersey and New York.

SOPHiA GENETICS is partnering with Agilent to offer a comprehensive solution for cancer analysis.

HUTCHMED Limited announces that, further to its announcement on January 23, 2023 and following the completion of customary closing conditions including antitrust regulatory reviews, the exclusive license agreement with a subsidiary of Takeda Pharmaceutical Company Limited to further the global development, commercialization and manufacture of fruquintinib outside China has closed.

ivWatch, LLC, a leader in IV safety and inventor of the first and only continuous IV infiltration detection technology, has been awarded a sole source group purchasing agreement with Premier, Inc. through its KIINDO pediatric performance group and collaborative.

National Institutes of Health researchers compared a new genetic animal model of Down syndrome to the standard model and found the updated version to be more similar to the changes seen in humans.

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the three months and full year ended December 31, 2022, and highlighted recent progress.

ORIC Pharmaceuticals, Inc., a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, announced that two abstracts have been accepted for poster presentations at the 2023 American Association for Cancer Research Annual Meeting taking place April 14-19, 2023, in Orlando, FL.